Key Identity Verification Trends for 2025: Regula's Expert Insights
21.1.2025 14:30:00 CET | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, unveils its vision for the identity verification (IDV) industry in 2025. As new and persistent threats converge with evolving regulations and user expectations, they bring to life new requests for significant technological advancements in IDV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121753818/en/
Regula's experts share their insights into how identity verification will evolve in 2025 (Graphic: Regula)
Threats shaping the IDV landscape
The rise in identity fraud over the past two years has significantly impacted all industries, especially Finance, Banking, FinTech, and Crypto. With deepfakes threatening every second company around the world, businesses won’t be able to stand out without liveness checks, both for biometrics and documents. However, organizations can’t blindly rely on this method as-is. They will have to introduce signal source control viahardware-enabled solutions. With deepfakes being so deeply realistic now, humans often fail to distinguish between what is fake and what is real. That is why checking signal source integrity is crucial, as it helps ensure that no injection is done during the video session within the IDV process.
Also, businesses will further reinforce their biometric verification methods, such as facial recognition, fingerprint scanning, and voice identification, as they add additional defense.
Interestingly, traditional threats like fake IDs and synthetic fraud still account for the majority of identity fraud attempts. This highlights the need for businesses to balance preparing for sophisticated future attacks with addressing the more prevalent threats of today.
Regulations and user expectations: Growing demand and pressure
The IDV landscape is evolving due to stricter laws, rising user expectations, and new workforce demands. Governments are enforcing tighter age verification to protect minors and regulate restricted services. This will be driving further technologies like biometric age estimation.
Users seek fast, personalized IDV solutions, while businesses require flexible systems. So, the IDV industry will continue developing toward user-centric design, where convenience and personalization are prioritized.
Additionally, a new IDV user category is emerging: the workforce. In the era of remote and hybrid work, identity verification for employees is critical to prevent fraud, such as fake identities and ghost employees.
Technological shifts
The evolving challenges of fraud, compliance, and user demands are driving advancements in IDV technologies and the adoption of new digital identity documentslike the Digital Travel Credential (DTC), mobile driver’s licenses (mDLs), digital identity, etc.
To ensure more efficient fraud prevention, identity verification will extend beyond traditional document and biometric checks to include additional methods, such as direct validation against governments’ or issuing authorities’ databases. Also, IDV technologies will be more deeply integrated with other IT solutions deployed in organizations to create secure ecosystems.
Journey Time Orchestration (JTO) is gaining traction, offering a dynamic platform approach to managing identity tasks across the user journey by unifying biometrics, passwords, and third-party systems to balance security and convenience.
Last but not least, AI and ML technologies will be gaining momentum in identity verification. They have been used in IDV solutions for some time already, but their influence will become more tangible as AI-generated fraud evolves into a very significant threat to businesses worldwide.
“The identity verification industry is driven by the multiple forces of advanced threats, rising user demands, tightening regulation, and technological advancements. As we move into 2025, the challenge will be to create solutions that not only address sophisticated fraud but also prioritize user convenience and regulatory compliance,” said Ihar Kliashchou, Chief Technology Officer at Regula.
To get more insights on the trends that will shape IDV in the coming year, read our blog article.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121753818/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom